Technology Transformation
The project has established a robust digital foundation for AstraZeneca’s Global Business Services, empowering them to fuel value creation across the organisation. This is achieved by unlocking the power of accurate and trustworthy data, enabling AstraZeneca to predict, act, and scale with greater confidence and precision.
AstraZeneca holds an unwavering commitment to accelerating the delivery of life-changing medications to patients worldwide. By 2030 AstraZeneca plan to grow revenue to $80bn, launch at least 20 new medicines, become industry leaders in Sustainability and improve operating margins. An ambitious set of goals. However, as an early adopter of ServiceNow, AstraZeneca had tailored the platform to meet evolving business needs, but this resulted in a federated eco-system of 16 bespoke instances, incomplete data and had become a barrier to achieving the cost efficient growth and innovation. Hampered by slow performance, inflexible processes, and costly upgrades, the process and technology landscape hindered AstraZeneca’s business and presented a significant risk to their core mission.
Deloitte embarked on a critical mission to replatform AstraZeneca’s ServiceNow platform. The initiative aimed to transform AstraZeneca’s ServiceNow ecosystem from a constraint to a strategic enabler of the company’s “Future of Work” initiative, focusing on optimising work allocation, location strategy, and employee experience to support ambitious growth targets while improving operating margins.
Deloitte was appointed as lead strategic partner, guiding AstraZeneca on scope, how to drive and delivers benefits through rebuilding key business capabilities within ServiceNow, driving out-of-the-box solutions to enable rapid adoption of new AI innovation and creating a new ‘Centre for Enablement’ operating model so the business can safely and rapidly drive innovation for themselves. Whilst the initial releases focussed on core functions like HR, IT, GBS, Procurement, and Finance, the platform is also being utilised by R&D and Commercial operations.
This was the broadest replatforming exercise ever undertaken globally which Deloitte successfully delivered in just nine months, significantly faster than the 18 months estimated by a number of other advisors. The programme has also leveraged GenAI and innovative Agentic AI capabilities to help liberate capacity and enable AZ to accelerate the delivery of life-changing medications to patients worldwide.
The project has established a robust digital foundation for AstraZeneca’s Global Business Services, empowering them to fuel value creation across the organisation. This is achieved by unlocking the power of accurate and trustworthy data, enabling AstraZeneca to predict, act, and scale with greater confidence and precision.
View the Deloitte profile in the MCA Members Directory.